Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 4Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 3Radiotherapy 3TIC10 compound 2Everolimus 2spartalizumab 1ribociclib 1olutasidenib 1lutetium Lu 177 dotatate 1lorlatinib 1larotrectinib 1etoposide phosphate 1balstilimab 1Vaccines 1Standard of Care 1Specimen Handling 1Proto-Oncogene Proteins c-akt 1Phosphatidylinositol 3-Kinases 1Ipilimumab 1Injections 1Immune Checkpoint Inhibitors 1GDC-0084 1Fluid Therapy 1Etoposide 1Eflornithine 1Diphtheria-Tetanus Vaccine 1Cetuximab 1CBLC137 1Biopsy 1Bevacizumab 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Diffuse Intrinsic Pontine Glioma × Eflornithine × Clear all
NCT06465199 2026-06-12

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡